Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness

Dranitsaris, George; Shane, Lesley G; Woodruff, Seth

doi:10.1177/1078155217727140

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LMWH is a favorable choice also in cancer patients unable to take oral pills due to nausea, vomiting, or anorexia [ 10 ]. Of note, tinzaparin presents a number of advantages compared to other LMWHs, including a once-daily curative dose, no need for a reduced dose over time, and a clear clinical benefit in the elderly and those with RI, essential in cancer patients who might require anticoagulant therapy indefinitely [ 11 ]. Nevertheless, tinzaparin remains relatively unknown and underused in CAT clinical practice [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review

Fioretti

Leopizzi

Puzzovivo

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) is the second main cause of cancer death with high related mortality and morbidity, leading to anticancer agent delays and interruptions. The recommended therapy, low-molecular-weight heparin (LMWH), however, is burdensome for patients and costly for society, as treatment should last until cancer is no longer active, even indefinitely. Tinzaparin is a manageable, efficient, safe, and cost-effective option. Compared to the other LMWHs, advantages are single-daily dose and safety in the elderly and those with renal impairment (RI). The purpose of this review is to critically discuss recent data on its efficacy and safety in CAT.

show abstract

Section: Introductionmentioning

confidence: 99%

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review

Fioretti

Leopizzi

Puzzovivo

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…However, in patients with possible pharmacokinetic changes, mainly including gravidas, obese patients and patients with a history or potential of VTE, routine testing of anti-Xa activity is recommended [ 16 ]. Although many clinical research studies have been conducted on the efficacy of LMWHs in the treatment of RSA, most of them focused on the prevention of venous thromboembolism (VTE) [ 17 – 19 ]. Few studies examined the effect of different LMWHs on anti-Xa levels of RSA patients.…”

Section: Introductionmentioning

confidence: 99%

Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

Bai

Zhang

Sun

et al. 2021

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Objective To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. Methods In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet. Results Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80 ± 0.22 IU/ml vs. 0.61 ± 0.24 IU/ml; P < 0.0001), although most patients in the three groups reached the target concentration of anti-Xa. Furthermore, patients in the enoxaparin group had a more stable anti-Xa levels during pregnancy. In addition, patients in the nadroparin group had a higher rate of local allergy than those in the enoxaparin group (60.5% vs. 42.5%; P = 0.004) and those in the dalteparin group (60.5% vs. 33.3%; P = 0.002). Further examination by the type of local allergy indicated a dramatic difference in pruritus and induration between the nadroparin group and the other two groups. No difference was found in the incidence of liver and renal dysfunction and thrombocytopenia. Conclusion Compared with nadroparin and daltepatin, enoxaparin showed a better performance regarding anti-Xa levels and the incidence of adverse reactions in the treatment of RSA.

show abstract

A retrospective study on potential drug interactions: A single center experience

Korucu

Şenyiğit

Köstek

et al. 2018

Journal of Oncological Sciences

View full text Add to dashboard Cite

Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness

Abstract: The totality of high-quality clinical and cost-effectiveness data supports the use of dalteparin over other low-molecular-weight heparins for preventing recurrent venous thromboembolism in patients with cancer.

Cited by 5 publications

References 31 publications

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review

Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

A retrospective study on potential drug interactions: A single center experience

Contact Info

Product

Resources

About